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Lamivudine and alpha interferon combination
treatment of patients with chronic hepatitis B
infection: a randomised trial
S W Schalm, J Heathcote, J Cianciara, G Farrell, M Sherman, B Willems, A Dhillon,
A Moorat, J Barber, D F Gray, International Lamivudine Study Group
Abstract
Background, aim, and methods—Alpha
interferon is the generally approved
therapy for HBe antigen positive patients
with chronic hepatitis B, but its eYcacy is
limited. Lamivudine is a new oral nucle-
oside analogue which potently inhibits
hepatitis B virus (HBV) DNA replication.
To investigate the possibility of an additive
eVect of interferon-lamivudine combina-
tion therapy compared with interferon or
lamivudine monotherapy, we conducted a
randomised controlled trial in 230 pre-
dominantly Caucasian patients with hepa-
titis B e antigen (HBeAg) and HBV DNA
positive chronic hepatitis B. Previously
untreated patients were randomised to
receive: combination therapy of lamivu-
dine 100 mg daily with alpha interferon 10
million units three times weekly for 16
weeks after pretreatment with lamivudine
for eight weeks (n=75); alpha interferon 10
million units three times weekly for 16
weeks (n=69); or lamivudine 100 mg daily
for 52 weeks (n=82). The primary eYcacy
end point was the HBeAg seroconversion
rate at week 52 (loss of HBeAg, develop-
ment of antibodies to HBeAg and unde-
tectable HBV DNA).
Results—The HBeAg seroconversion rate
at week 52 was 29% for the combination
therapy, 19% for interferon monotherapy,
and 18% for lamivudine monotherapy
(p=0.12 and p=0.10, respectively, for com-
parison of the combination therapy with
interferon or lamivudine monotherapy).
The HBeAg seroconversion rates at week
52 for the combination therapy and lami-
vudine monotherapy were significantly
diVerent in the per protocol analysis (36%
(20/56) v 19% (13/70), respectively;
p=0.02). The eVect of combining lamivu-
dine and interferon appeared to be most
useful in patients with moderately
elevated alanine aminotransferase levels
at baseline. Adverse events with the
combination therapy were similar to in-
terferon monotherapy; patients receiving
lamivudine monotherapy had signifi-
cantly fewer adverse events.
Conclusions—HBeAg seroconversion
rates at one year were similar for lamivu-
dine monotherapy (52 weeks) and stand-
ard alpha interferon therapy (16 weeks).
The combination of lamivudine and inter-
feron appeared to increase the HBeAg
seroconversion rate, particularly in pa-
tients with moderately elevated baseline
aminotransferase levels. The potential
benefit of combining lamivudine and
interferon should be investigated further
in studies with diVerent regimens of com-
bination therapy.
(Gut 2000;46:562–568)
Keywords: chronic hepatitis B; hepatitis B virus;
nucleoside analogue; lamivudine; alpha interferon;
combination therapy; HBeAg seroconversion
Until recently, the only generally approved
treatment for chronic hepatitis B was alpha
interferon, which is a natural antiviral agent but
acts primarily by immunomodulation.1 The
eYcacy of interferon is variable, with rates of
hepatitis B e antigen (HBeAg) loss ranging
from 15 to 37%.2–4 Virological response rates
are higher in patients with elevated serum
aminotransferases which presumably reflects
the immune activity to the virus.5 6 Interferon
treatment is associated with considerable but
tolerable side eVects in approximately 90% of
patients.7 8
Lamivudine is an oral nucleoside analogue
that inhibits hepatitis B virus (HBV) DNA
synthesis by chain termination.9 Previous clini-
cal trials have shown that lamivudine treatment
rapidly suppresses HBV replication, enhances
aminotransferase normalisation, improves his-
tological outcome, and has an excellent safety
profile.10–12 HBeAg seroconversion, the surro-
gate marker with predictive value for improved
survival,13 14 was observed in 16% of Asian
patients after one year of lamivudine therapy.12
Since the two drugs have diVerent mecha-
nisms of action, we conducted a study to deter-
mine if combination treatment with both lami-
vudine and interferon had an additive eVect
against HBV and would lead to higher HBeAg
seroconversion rates than either monotherapy.
Materials and methods
PATIENTS
Eligible patients included males and females,
16–70 years of age, with detectable hepatitis B
surface antigen (HBsAg) and HBeAg in serum
at the time of screening and for at least six and
three months, respectively, before study entry;
serum HBV DNA levels of at least 5 pg/ml at
Abbreviations used in this paper: HBV, hepatitis B
virus; HBsAg, hepatitis B surface antigen; HBeAg,
hepatitis B e antigen; ALT, alanine aminotransferase;
ULN, upper limit of normal.
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screening (solution hybridisation assay, Ab-
bott, Chicago, USA); and evidence of inflam-
mation by histology or by raised alanine
aminotransferase (ALT) levels (1.3–10 × the
upper limit of normal (ULN)) at screening and
at least once three months before screening
with no value falling within the normal
reference range in the intervening period.
Patients were excluded at screening if they
had been treated previously with interferon or
had received antiviral medications within six
months; were co-infected with hepatitis C,
hepatitis D or HIV; had decompensated liver
disease (serum bilirubin more than 2.5×ULN,
prothrombin time prolonged more than three
seconds, serum albumin less than the lower
limit of normal, a history of ascites, variceal
haemorrhage or hepatic encephalopathy); had
evidence of liver disease of other aetiology
(toxic, immune); or any contraindications
specified for interferon.
The study was conducted in accordance with
the guidelines of the Declaration of Helsinki
and its subsequent amendments. All patients
gave written informed consent. The study was
approved by the ethics committees at partici-
pating centres.
STUDY DESIGN
Patients eligible at screening returned for a
baseline assessment within four weeks. At
baseline (day 1), patients were randomised to
receive one of the following three treatment
regimens: (i) combination treatment: eight
weeks of oral lamivudine 100 mg once daily
followed by 16 weeks of lamivudine 100 mg
once daily and alpha interferon (Intron A,
Schering Plough, Kenilworth, USA) 10 million
units three times weekly subcutaneously†; (ii)
interferon monotherapy: eight weeks of oral
placebo once daily followed by 16 weeks of
placebo once daily and interferon 10 million
units three times weekly; and (iii) lamivudine
monotherapy: lamivudine 100 mg once daily
for 52 weeks‡. Treatment was allocated in
blocks of six per investigational centre (ratio of
random assignment to the three treatment
regimens: 2:2:2); the randomisation code was
computer generated.
All treatment arms were blinded up to week
8. At week 8, investigators opened sealed enve-
lopes corresponding to patients’ treatment
numbers which contained instructions on
whether or not to dispense interferon. On
opening the envelopes, the lamivudine mono-
therapy arm eVectively became unblinded
although the interferon and combination arms
remained blinded. Results of HBV serology
were kept blinded during treatment and follow
up. Patients were followed up after treatment
cessation to week 64 (end of the study): 12
weeks of follow up for lamivudine patients and
40 weeks of follow up for patients who received
interferon or the combination treatment.
The primary outcome measure was HBeAg
seroconversion at week 52 (loss of HBeAg,
development of antibodies to HBeAg (anti-
HBe), and undetectable HBV DNA). Second-
ary eYcacy variables included histological
response (reduction in Knodell score by at least
2 points in the biopsy at week 52), HBV DNA
loss, and ALT normalisation at week 52.
MONITORING
Patients returned for assessments every four
weeks after the baseline visit until the end of the
treatment and thereafter every 4–8 weeks.
Serum was analysed for HBV DNA, HBeAg,
and anti-HBe at various times between base-
line and the end of study, with key points at
weeks 24, 52, and 64. Serum was analysed for
the presence of YMDD variant HBV at week
52 and week 64. Biochemistry and haematol-
ogy laboratory evaluations and adverse events
were assessed at each clinic visit. Patients were
requested to have had a liver biopsy within 12
months of the study baseline, and at week 52.
LABORATORY METHODOLOGY
Viral markers were assayed at a single reference
laboratory (Covance, Harrogate, UK). Serum
HBV DNA was quantified by a solution-
hybridisation assay (Abbott, Chicago, USA)
with a lower limit of quantitation of 3.0 pg/ml
of serum (approximately 8×106 copies of HBV
DNA, Eurohep standard). HBeAg, anti-HBe,
and HBsAg were assessed by qualitative micro-
particle enzyme immunoassay (Abbott). The
incidence of YMDD variant HBV DNA was
assessed by a restriction fragment length poly-
morphism assay, as described by Lai and
colleagues.12 The assay performed at Glaxo
Wellcome, Triangle Park, USA, had a lower
limit of detection of approximately 500 copies
of HBV DNA/ml of serum.
Liver biopsy specimens were randomly
assigned a predetermined computer generated
code at Glaxo Wellcome and sent for histologi-
cal assessment to a single independent his-
topathologist who was blinded with respect to
patient identity, treatment assignment, date,
and sequence of biopsy specimen. The biopsy
specimens were scored according to the
Knodell histological activity index.15
STATISTICAL ANALYSES
Based on an estimated rate of HBeAg serocon-
version at 52 weeks of 40% for interferon and
lamivudine monotherapy and 65% for the
combination therapy, a sample size of 210
patients was calculated to provide 80% power
to detect a significant diVerence in HBeAg
seroconversion rates between the combination
treatment and interferon, and the combination
and lamivudine monotherapy. The study was
†An initial eight week pretreatment period with
lamivudine was included in the combination arm
design to reduce HBV DNA load before the
combination treatment as low HBV DNA levels have
been significantly associated with improved response to
interferon.3 6
‡The original study design had a lamivudine
monotherapy arm with a six month treatment duration
for comparison with the combination and interferon
treatment arms. However, emerging results from phase
II studies11 indicated lamivudine therapy of longer than
six months duration was required for significant
HBeAg seroconversion. The protocol was
consequently amended to extend the duration of the
lamivudine monotherapy arm to 12 months.
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not powered to establish whether the HBeAg
seroconversion rates were equivalent between
lamivudine and interferon monotherapies.
The primary population for the eYcacy
analyses was the intent to treat population
(ITT). The ITT population was defined as
patients with confirmed chronic hepatitis B
(i.e. patients who were HBsAg positive for at
least six months at screening and had evidence
of ALT elevation (>ULN) and/or histological
evidence of inflammation by a Knodell HAI
score >2 points) who were randomised to
treatment.
A secondary analysis, for the primary end
point only, was performed on a subpopulation
of the ITT population referred to as the per
protocol population. This population was
redefined retrospectively due to the unex-
pected variability in hepatitis B virus markers
between screening and baseline. The criteria
for patient inclusion in the per protocol popu-
lation were positivity for HBeAg and HBV
DNA at baseline, use of trial medication
according to the randomisation and protocol,
and non-use of prohibited medications.
Safety data were analysed by treatment
received for all patients who were given at least
one dose of study medication (“as treated
population”).
Missing data for HBeAg, anti-HBe, and
HBsAg parameters were assigned values based
on the method of last observation carried
forward. In the analysis of HBeAg seroconver-
sion, a patient was considered to have serocon-
verted if it occurred prior to withdrawal or a
missing HBV DNA value. In the analysis of
ALT and HBV DNA, missing data were
considered as failures (HBV DNA detectable
or ALT above the normal reference range).
The Cochran-Mantel-Haenzsel test adjusted
for centre, or Fisher’s exact test was used to
compare diVerences in proportions between
treatment groups. A supplementary analysis of
HBeAg seroconversion at week 52 for the ITT
population was performed using generalised
estimating equation analysis16 to address the
issue of small centres; the results were similar
to those using Cochran-Mantel-Haenzsel. All p
values are two sided.
Results
STUDY POPULATION
Fifty one centres from 15 countries partici-
pated in recruitment between July 1994 and
June 1996. A total of 310 patients were
screened, of which 230 patients were ran-
domised to treatment. Patients who failed the
screening were mainly those who did not dem-
onstrate persistent HBV DNA positivity or
those with ALT values <1.3×ULN.
Of the 230 patients randomised to treat-
ment, 226 fulfilled the entry criteria of HBsAg
positivity for longer than six months and
evidence of disease activity at screening (ITT
population). The numbers of patients in the
ITT population randomised to the combina-
tion treatment, interferon monotherapy and
lamivudine monotherapy were 75, 69, and 82,
respectively (fig 1). The per protocol popula-
tion comprised 180 patients: 15 patients had
HBV serological ineligibility at baseline, 28
patients were non-compliant with the study
medication, one patient received prohibited
medications and eight patients were incorrectly
dispensed medication (some patients appeared
in more than one violation category).
The as treated population consisted of all 230
patients but was analysed by treatment received
rather than by treatment allocated (fig 1).
All treatment arms were well matched with
regard to baseline characteristics (table 1).
PRIMARY EFFICACY MEASURE (FIG 2)
HBeAg seroconversion
At week 52, the rate of HBeAg seroconversion
was 29% (20/68) for the combination group,
19% (12/64) for interferon, and 18% (14/80) for
lamivudine monotherapy (combination group v
interferon: odds ratio 1.9 (confidence interval
(95% CI) 0.8–4.4), p=0.12; combination
Figure 1 Progress of patients through the various stages of the trial.
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groups v lamivudine: odds ratio 2.0 (95% CI
0.9–4.7), p=0.10, ITT analysis). Of the 14
lamivudine treated patients who had serocon-
verted by week 52, 81% (9/11 of those followed
up) were maintained oV therapy through to
week 64 (fig 2).
In the per protocol population analysis, the
HBeAg seroconversion rate at week 52 was
36% (20/56) in the lamivudine-interferon
combination group, 22% (12/54) in the
interferon group and 19% (13/70) in the lami-
vudine group. The HBeAg seroconversion rate
in the combination group was significantly
higher than that for lamivudine monotherapy
(odds ratio 3.3 (95% CI 1.2–8.8), p=0.02) but
failed to reach significance compared with
interferon monotherapy (odds ratio 2.3
(95% CI 0.9–5.5), p=0.07).
In a subgroup analysis, the HBeAg serocon-
version rate was determined for three catego-
ries of baseline ALT. The HBeAg seroconver-
sion rate in the total study population was
diVerent for the three categories, with the low-
est rate for patients with serum ALT <2×ULN
(11%, 9/82) and the highest rate for patients
with serum ALT levels >5×ULN (38%,
13/34). The combination therapy appeared to
increase the HBeAg seroconversion rate pre-
dominantly in those with baseline serum ALT
>2× and <5×ULN (fig 2).
SECONDARY EFFICACY MEASURES
Histological findings
Paired liver biopsy slides, at pretreatment and
at week 52, were available for 77% (174/226) of
patients. The histological response (reduction
in HAI score by >2 points) was 37% (21/57)
for patients receiving the combination treat-
ment, 46% ((25/54) for interferon, and 49%
(31/63) for lamivudine. Evidence of histologi-
cal progression (worsening) of liver disease
(increase in HAI score by >2 points) was 30%
(17/57) for the combination group, 31%
(17/64) for interferon, and 11% (7/63) for
lamivudine. No diVerences between the combi-
nation therapy and interferon monotherapy
were observed.
ALT normalisation and loss of HBV DNA
Data for ALT normalisation and loss of HBV
DNA are given in table 2. Data are presented as
point prevalence at weeks 24, 52, and 64.
Table 1 Patient characteristics at entry to the study
Characteristic
Treatment group
Total
(n=226)
Lam/interferon
(n=75)
Interferon
(n=69)
Lamivudine
(n=82)
Age (years) (median (range)) 31 (15–60) 32 (16–70) 30 (16–69) 31 (15–70)
Sex (% male) 71 81 71 74
Weight (kg) 72.0 (42–115) 71.0 (45–115) 68.5 (45–118) 70.4 (42–118)
Ethnicity (%)
Caucasian 59 65 65 63
Asian-Oriental 31 28 29 29
ALT (×ULN)
Median (range) 2.2 (0.8–26.1) 2.4 (0.8–10.1) 2.6 (0.8–19.2) 2.4 (0.8–26.1)
Mean (SD) 3.2 (3.4) 3.1 (2.1) 3.3 (2.8) 3.2 (2.8)
<1×ULN (No (%)) 4 (5) 3 (4) 4 (5) 11 (5)
HBV DNA (pg/ml)
Median (range) 94.0 (1.5–786) 109.0 (1.5–1322) 136.0 (1.5–2264) 113.5 (1.5–2264)
Mean log10 (SD) 1.74 (0.75) 1.78 (0.77) 2.04 (0.66) 1.86 (0.73)
<3 pg/ml 4 (5) 9 (13) 2 (2) 11 (5)
Positive for HBeAg (No (%)) 72 (96) 68 (99) 81 (99) 221 (98)
Positive for HBV DNA and HbeAg (No (%)) 68 (91) 64 (93) 80 (98) 212 (94)
Knodell HAI score
Median (range) 4 (0–14) 4 (0–13) 4 (0–12) 4 (0–14)
<2 8 (11) 6 (9) 11 (5) 18 (8)
Evidence of cirrhosis (No (%)) 3 (4) 8 (12) 5 (6) 16 (7)
Evidence of cirrhosis is indicated by a score of 4 on the fibrosis component of Knodell histological activity index score. HBV DNA
values below 3 pg/ml (lower limit of detection) have been set to 1.5 pg/ml in the calculation of summary statistics.
Figure 2 Percentage HBeAg seroconversion for the three treatment arms (lamivudine-interferon, interferon, and
lamivudine) by various times (left) and by baseline ALT levels at week 52 (right). The number of patients in each category
is given above the bar.
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Incidence of YMDD variant HBV
The incidence of YMDD variant HBV was
evaluated in all patients where serum samples
were available at weeks 52 or 64, or both.
YMDD variant HBV variants were not de-
tected in any serum sample from interferon or
combination treated patients.
At week 52, 21% (13/61) of patients who
were treated with lamivudine were HBV DNA
PCR negative, 31% (19/61) had a YMDD
variant HBV, and 48% (29/61) had wild type
HBV. At week 64, 21% (12/57) had YMDD
variant HBV, indicating the re-emergence of
the wild type virus after stopping lamivudine
treatment.
SAFETY
The percentage of patients completing treat-
ment was 92 (70/76) for the combination
treatment, 91 (64/70) for interferon at 24
weeks and 83 (70/84) for lamivudine at 52
weeks. Withdrawals by week 52 are summa-
rised in fig 1. Five patients withdrew before
completing treatment because of adverse
events; the reason for withdrawal in the
lamivudine group was asymptomatic raised
serum transaminases two weeks after the start
of therapy (one patient) and asymptomatic
elevated CPK levels (two patients); in the com-
bination group, one patient withdrew because
of fever, chills, and insomnia, and another
patient because of fatigue, headache, and men-
tal disturbance. There were no withdrawals
caused by adverse events in patients treated
with interferon only.
Other reasons for discontinuation included
pregnancy, emigration, non-compliance or the
patient’s request to withdraw for non-specific
reasons.
The most common adverse events are
summarised in table 3. There was a high
incidence of headache in the combination
group (71%, 54/76) but other adverse events
were similar in the combination and interferon
groups. The incidence of adverse events for the
interferon regimens was much higher than that
observed for lamivudine therapy, despite the
longer treatment duration; the diVerence was
significant (p<0.002) for headache, muscle
pain, anorexia, malaise and fatigue, fever/chills,
and hair loss.
In approximately 20% of patients in the
interferon and combination groups, the inter-
feron dose was adjusted during the study.
Hepatitis flares (ALT levels >500 IU/l and
>2×baseline) were observed during and after
treatment. During treatment, flares occurred in
12% (10/82) of patients who received lamivu-
dine, in 11% (8/70) of interferon recipients,
and in 0% (0/75) of those given the combina-
tion therapy.
Post-treatment, the incidence of hepatitis
flares was 13% (10/78) in the lamivudine
group, 9% (6/68) in the interferon group, and
7% (5/74) in the combination group. Three of
the hepatitis flares (two lamivudine, one inter-
feron) were associated with elevation of serum
bilirubin (>2×ULN); all events resolved spon-
taneously.
Discussion
In this study of HBeAg positive chronic hepati-
tis B patients of predominantly Caucasian ori-
gin, HBeAg seroconversion rates were similar
after 52 weeks of lamivudine monotherapy
(18%) and 16 weeks of interferon therapy
(19%). However, a combination of 24 weeks of
lamivudine and 16 weeks of interferon pro-
duced a higher HBeAg seroconversion rate
(29%).
The rate of HBeAg seroconversion of 19%
for the interferon monotherapy group appears
low compared with the generally quoted rate of
33% for loss of HBeAg.4 The low rate of
HBeAg seroconversion in our study partly
reflects the use of the most stringent definition
of response (HBeAg seroconversion v loss of
HBeAg). Also, our study population had lower
mean baseline ALT values (3.2×ULN) com-
pared with patients studied by Perillo and
colleagues3 (4.3×ULN) and a HBeAg loss rate
of 37%. The rate of HBeAg loss for interferon
in this study was 23% compared with 29% in a
recently published European study17; in pa-
tients with a low mean baseline ALT, loss of
HBeAg even fell to 15%.2 These data reinforce
the conclusion of a European meta-analysis
based on individual patient data5 that the eVect
of alpha interferon is relative to baseline ALT
levels and that the absolute benefit seems
greatest in patients with high serum ALT
levels.
The HBeAg seroconversion rate after 52
weeks of lamivudine monotherapy (18%)
observed in our trial was similar to the HBeAg
seroconversion rate of 16% reported by Lai
Table 2 Secondary eYcacy measures: point prevalence in percentages (intention to treat
population eligible for response at baseline)
Outcome measure
Time
(week)
Lam/interferon
(n=68)
Interferon
(n=64)
Lamivudine
(n=80)
HBeAg loss 24 19 (62) 11 (57) 14 (70)
52 35 (55) 23 (56) 23 (60)
64 33 (55) 29 (48) 21 (62)
HBV DNA loss 24 84 (62) 30 (57) 64 (70)
52 36 (55) 29 (55) 60 (60)
64 31 (55) 29 (49) 32 (63)
ALT normalisation 24 34 (62) 21 (58) 51 (72)
52 38 (55) 29 (55) 57 (58)
64 36 (50) 32 (50) 21 (63)
HBeAg loss is defined as undetectable (AS×YM, Abbott); HBV DNA loss is defined as HBV DNA
values below the cut oV (3 pg/ml, Abbott HBV DNA test); ALT normalisation is defined as
<1.0×ULN. Number of patients is indicated in parentheses.
Table 3 Most common adverse events during treatment (number of patients)
Lam/interferon
(n=76)
Interferon
(n=70)
Lamivudine
(n=84)
Viral respiratory infections 32 37 25
Headache 71* 47 27†
Muscle pain 36 40 11†
Abdominal discomfort and pain 11 23 13
Diarrhoea 14 16 13
Malaise and fatigue 66 70 35†
Arthralgia 9 23 4
Anorexia 30 33 4†
Dizziness 9 19 8
Nausea and vomiting 33 34 19
Fever/chills 46 43 6†
Hair loss and alopecia 30 21 8†
Most common adverse events defined as those occurring during treatment in>15% of patients in
any treatment group.
*p value: lam/interferon v interferon: 0.004 (borderline significant in view of multiple testing); †p
value lam/interferon v lamivudine: <0.002 (significant after correction for multiple testing).
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and colleagues12 after one year of lamivudine
treatment in Asian patients.
Clearance of HBeAg after interferon treat-
ment is reported to be sustained in approxi-
mately 90% of patients and associated with an
improved clinical outcome in long term follow
up studies.14 All lamivudine treated patients
who HBeAg seroconverted are currently being
followed up long term; HBeAg seroconversion
is reported to be approximately 90% at six
months post-treatment.18 Thus our data sug-
gest that lamivudine for 52 weeks has the
potential to induce prolonged HBeAg serocon-
version in patients with chronic hepatitis B at a
similar rate to that of a 16 week course of inter-
feron treatment.
The combination of lamivudine with inter-
feron appeared to be associated with a higher
HBeAg seroconversion rate compared with
either form of monotherapy. In this study, the
eYcacy of the combination therapy was most
pronounced in patients with moderately
elevated baseline ALT (2–5×ULN). In patients
with high ALT levels (>5×ULN), no addi-
tional eVect of combining interferon and lami-
vudine on the HBeAg seroconversion rate was
observed. Seroconversion based on baseline
ALT categories (<2×ULN, 2–5×ULN,
>5×ULN) in the present study are consistent
with the results of Liaw (data on file at Glaxo
Wellcome) in Asian patients and underlines the
importance of this baseline feature for the pre-
diction of HBeAg seroconversion. These ex-
ploratory findings require confirmation in a
prospective study.
Patients who received lamivudine mono-
therapy derived histological benefit, irrespec-
tive of their HBeAg seroconversion status,12
whereas the histological response after inter-
feron treatment is usually observed only in
patients who have demonstrated a serological
response.19 Results from this study agree with a
previous report12 indicating improvement in
histological inflammation in patients after one
year’s lamivudine treatment.
The incidence of YMDD variant HBV DNA
after one year of lamivudine therapy was 31%
in this study; this is higher than that previously
reported in Asian patients (14%)12 but similar
to that in a recent series of Caucasian
patients.20 The reason for this discrepancy is
uncertain but is probably related to diVerences
in study populations. When lamivudine treat-
ment was stopped at week 52 in patients with
YMDD variant HBV, there was re-emergence
of the wild type virus. The long term clinical
outcome and significance of YMDD variant
HBV are being evaluated in ongoing follow up
clinical trials.
No serious side eVects were observed in this
study with the use of these two agents in com-
bination, as previously suggested.21 The high
incidence of headache and hair loss needs to be
evaluated further. The incidence of drug
related adverse events was much lower with
lamivudine monotherapy compared with inter-
feron therapy, and similar to that observed in
Asian patients receiving lamivudine or
placebo.12
In conclusion, HBeAg seroconversion rates
at one year were similar for lamivudine mono-
therapy and a standard course of interferon.
Combination therapy may be more eVective
than either monotherapy. Studies with other
regimens regarding duration of lamivudine and
interferon therapy are needed to identify
subgroups of patients in whom combination
therapy may be the best treatment option.
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